ThromboGenics Announces Start Of Phase II Trial Of Microplasmin For The Treatment Of Age-Related Macular Degeneration (AMD)
LEUVEN, Belgium, December 11 /PRNewswire/ -- ThromboGenics NV , a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, announces today that it has…